Globus Medical (GMED) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 rises as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Morgan Stanley Downgrades Globus Medical (GMED) to Equalweight
July 27, 2016 3:02 PM EDTMorgan Stanley downgraded Globus Medical (NYSE: GMED) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Globus Medical click here. For more ratings news on Globus Medical click here.
Shares of Globus Medical closed at $26.43 yesterday.
... MoreUPDATE: Canaccord Genuity Downgrades Globus Medical (GMED) to Hold
July 27, 2016 7:17 AM EDT(Updated - July 27, 2016 10:39 AM EDT)
Canaccord Genuity downgraded Globus Medical (NYSE: GMED) from Buy to Hold with a price target of $28.00 (from $30.00). Analyst Kyle Rose expressed concerns that its US business slow to regain momentum.
Rose explained, "We... More
Wells Fargo Upgrades Globus Medical (GMED) to Market Perform
July 27, 2016 7:16 AM EDTWells Fargo upgraded Globus Medical (NYSE: GMED) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Globus Medical click here. For more ratings news on Globus Medical click here.
Shares of Globus Medical closed at $26.43 yesterday.
... MoreLeerink Partners Downgrades Globus Medical (GMED) to Market Perform
July 27, 2016 7:12 AM EDTLeerink Partners downgraded Globus Medical (NYSE: GMED) from Outperform to Market Perform with a price target of $27.00 (from $29.00).
Analyst Richard Newitter commented, "We appreciate that GMED's above avg. EBITDA margin profile has held up despite decelerating 1H16 rev. growth, and acknowledge a better 2017 set-up as comps get easier and key investment initiatives like... More
